Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥66.00 - ¥220.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥5.81B
Enterprise Value¥2.59B
Total Cash (Recent Filing)¥2.45B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Jul 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.68
Shares Outstanding76,392,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetMaintaining no reported debt materially reduces fixed obligations and interest risk, preserving strategic optionality to fund R&D or pursue partnerships. Over the next several months this structural flexibility supports continuing clinical programs without near-term interest burdens or covenant constraints.
Proven Prior Revenue And Profitability (2023)Having produced revenue and positive net income in 2023 demonstrates the company can commercialize assets and reach breakeven. This reduces the binary risk typical of early biotech firms, supporting credibility with partners and investors and increasing the likelihood of reattaining revenue when programs progress.
Focused Oncology Small-molecule R&D StrategyA clear, focused therapeutic strategy in oncology and small-molecule discovery aligns with enduring global demand for cancer treatments. Concentrated expertise plus a lean team can enable efficient target development and make the company an attractive collaborator for licensors or larger pharma seeking specialized assets.
Bears Say
Zero Recent Revenue And Widening LossesA return to zero revenue coupled with sharply larger losses indicates the company is not currently generating operating cash inflows, undermining margin sustainability and increasing dependency on external financing. Over a 2–6 month horizon this elevates execution and funding risk for development programs.
Sustained Negative Operating And Free Cash FlowPersistent large operating cash outflows deplete reserves and shorten runway absent new funding. This structural cash burn makes dilution or asset-sales likely, constraining long-term program funding, slowing development timelines, and reducing bargaining leverage with partners or acquirers.
Eroding Equity And Weakened Capital BaseMaterial erosion of shareholders' equity reflects cumulative losses and reduces the company's financial cushion to absorb setbacks. A smaller capital base limits optionality for self-funding trials, increases reliance on external capital, and raises the risk that adverse outcomes prompt aggressive financing terms or asset disposals.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥66.00 and its highest was ¥220.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥5.81B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Jul 15, 2026 which is in 14 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Apr 10, 2026. The company reported -¥4.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.71.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 76,392,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥4.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―